Almac starts controlled drug operations at US HQ

By Gareth Macdonald

- Last updated on GMT

Controlled substance supply operations are up and running at Almac’s facility in Souderton, Pennsylvania after the CMO completes the latest stage of relocation to new North American HQ.

The unit includes 3,980 sq ft of high security storage space, as well as packaging and distribution areas for compounds covered by the US Drug Enforcement Administration’s (DEA) schedule I – V regulations.

Spokesman Jonathon Calderwood told that pharmaceutical industry demand and the evolution of the drug sector were the key drivers for Almac’s investment.

Controlled drugs in terms of clinical supply are increasing in prominence as Pharma looks to shift beyond the blockbuster development models and move into targeted, niche therapies​.”

He went on to explain that the firm has provided storage and packaging of controlled drugs for some time “but now [with the new unit] we have aimed to provide extensive capacity for these product types.

Also​,” Calderwood continued “global distribution and supply chain management of controlled substance clinical supplies is a growing service area, so we are also progressing the supply chain management aspect via our global distribution depot network​.”

The Northern Ireland-headquartered firm has been moving into the Souderton facility in a phased transition programme that began last September​ with the installation of its analytical testing and clinical supplies units.

Since then Almac has opened a clinical technologies unit, which runs the firms trial monitoring and reporting technology business, and a pharmacy and distribution warehouse.

And, just last month, the contract research organisation (CRO) announced that the Souderton, Pennsylvania facility’s contract analytical laboratories had been made operational.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers